MarketCap
Eli Lilly and Company LLY
$ 1 277.31
-0.56%
Facebook
X
Telegram
Eli Lilly and Company ROA Ratio | LLY
Annual ROA Ratio Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.35 | 13.45 | 8.19 | 12.62 | 11.44 | 13.28 | 21.17 | 7.36 | -0.45 | 7.05 | 6.77 | 6.43 | 13.29 | 11.89 | 12.92 | 16.35 | 15.76 | -7.09 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.17 | -7.09 | 10.49 |
Quarterly ROA Ratio Eli Lilly and Company
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.8 | 19.9 | 14.84 | 14.11 | 12.01 | 8.82 | 10.75 | 9.15 | 8.71 | 12.86 | 11.95 | 9.42 | 12.33 | 9.27 | 12.16 | 8.11 | 10.7 | 11.42 | 11.64 | 8.74 | 12.55 | 13.15 | 13.5 | 21.17 | 19.93 | 19.36 | 15.39 | 7.36 | 1.12 | -0.27 | 2.57 | -0.45 | 5.22 | 5.99 | 5.67 | 7.05 | 6.41 | 6.65 | 6.42 | 6.77 | 6.61 | 5.71 | 5.99 | 6.46 | 7.34 | 9.41 | 10.86 | 13.29 | 13.63 | 14.07 | 13.34 | 11.89 | 13.15 | 12.85 | 13.31 | 10.37 | 14.72 | 15.92 | 16.95 | 17.28 | 17.23 | 4.59 | 3.47 | 4.3 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.8 | -0.45 | 10.58 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Reata Pharmaceuticals
RETA
|
-60.62 | - | - | $ 6.29 B |  USA |
 |
ObsEva SA
OBSV
|
-126.77 | - | -15.52 % | $ 10.5 M |  Schweiz |
 |
PolarityTE
PTE
|
-34.28 | - | -0.82 % | $ 1.78 M | USA |
 |
Kronos Bio
KRON
|
-69.22 | - | 1.49 % | $ 50.8 M | USA |
 |
Landos Biopharma
LABP
|
-57.66 | - | 0.58 % | $ 144 M | USA |
 |
Myovant Sciences Ltd.
MYOV
|
-39.61 | - | -0.04 % | $ 2.62 B | USA |
 |
Poseida Therapeutics
PSTX
|
-45.07 | - | - | $ 857 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
Trevena
TRVN
|
-99.22 | - | -46.58 % | $ 31.8 M | USA |
 |
Virpax Pharmaceuticals
VRPX
|
-775.72 | - | -45.12 % | $ 2.85 M | USA |
 |
Oncorus
ONCR
|
-53.18 | - | -8.54 % | $ 3.19 M | USA |
 |
Y-mAbs Therapeutics
YMAB
|
-24.74 | - | - | $ 382 M | USA |
 |
Navidea Biopharmaceuticals
NAVB
|
-347.18 | - | -2.99 % | $ 2.47 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
-104.58 | - | - | $ 23.9 M | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Satsuma Pharmaceuticals
STSA
|
-127.51 | - | -0.9 % | $ 36.5 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-44.67 | $ 1.29 | -3.38 % | $ 110 M | USA |
 |
SpringWorks Therapeutics
SWTX
|
-43.95 | - | - | $ 3.48 B | USA |
 |
Metacrine
MTCR
|
-77.77 | - | - | $ 24.2 M | USA |
 |
Turning Point Therapeutics
TPTX
|
-23.57 | - | -0.13 % | $ 3.73 B | USA |
 |
Infinity Pharmaceuticals
INFI
|
-105.26 | - | -46.98 % | $ 3.57 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
-156.23 | - | 31.87 % | $ 1.61 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M |  Israel |
 |
Evelo Biosciences
EVLO
|
-177.72 | - | -14.46 % | $ 27.9 M | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Morphic Holding
MORF
|
-21.05 | - | - | $ 2.42 B | USA |
 |
Novan
NOVN
|
-34.66 | - | -24.84 % | $ 2.64 M | USA |
 |
Genocea Biosciences
GNCA
|
-59.31 | - | -15.0 % | $ 3.04 M | USA |
 |
Equillium
EQ
|
-70.24 | $ 1.23 | -0.41 % | $ 70.5 M | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
-193.07 | - | -9.21 % | $ 2.55 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
BELLUS Health
BLU
|
-18.66 | - | - | $ 2.47 B |  Canada |
 |
bluebird bio
BLUE
|
-52.3 | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
-1.24 | - | - | $ 13.6 B | USA |
 |
IGM Biosciences
IGMS
|
-73.69 | - | - | $ 76.9 M | USA |
 |
Marinus Pharmaceuticals
MRNS
|
-82.74 | - | - | $ 29.6 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-6.15 | - | - | $ 216 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-42.62 | - | - | $ 35.4 M | USA |
 |
ContraFect Corporation
CFRX
|
-315.07 | - | -5.16 % | $ 5.39 M | USA |
 |
Sigilon Therapeutics
SGTX
|
-49.91 | - | - | $ 728 M | USA |
 |
Rubius Therapeutics
RUBY
|
-778.79 | - | -33.55 % | $ 7.81 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
TRACON Pharmaceuticals
TCON
|
-35.51 | - | -1.38 % | $ 46.8 M | USA |
 |
Edesa Biotech
EDSA
|
-53.11 | $ 2.56 | -7.58 % | $ 14.5 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-313.34 | $ 17.42 | 8.67 % | $ 236 M | USA |
 |
Mirati Therapeutics
MRTX
|
-61.6 | - | - | $ 3.3 B | USA |
 |
Revance Therapeutics
RVNC
|
-67.72 | - | - | $ 309 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
-55.73 | - | -37.48 % | $ 476 K | USA |
 |
Epizyme
EPZM
|
-86.89 | - | - | $ 249 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-104.83 | - | -9.72 % | $ 5.89 M | USA |